Factors associated with pain in oral cavity and
oropharyngeal cancer patients during radiation therapy
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Introduction

Results

Oral cavity and oropharyngeal cancers (OC/OPC) is estimated to affect 54,000 people
annually in the United States [1]. Radiation therapy is often standard of care, but it is
known to cause significant pain and can decrease overall quality of life. Causes of pain
can include mucositis, xerostomia, and acute skin reactions. The average pain score
during week 1 of treatment is 1.5 and increases to 5 by week 7 (p < 0.05). This
demonstrates how there is no control for pain as patients experience a significant level
of pain throughout their treatment. We hypothesize that concurrent chemotherapy will
lead to increased pain. Identifying pain causing factors could help physicians better
manage patients’ pain levels.

Concurrent Chemotherapy

The objective of this study is to assess the effect of concurrent chemotherapy, cancer
type, and gender on pain profiles for OC/OPC patients who receive radiation therapy.
Figure 1. Location of the oral cavity and
oropharynx [2]. Oral cavity includes oral
tongue, gingiva, retromolar trigone,
mandible, buccal mucosa, lip, hard
palate, and floor of mouth. Oropharynx
includes soft palate, tonsils, base of
tongue, glossopharyngeal sulcus, and
pharyngeal wall.

Figure 2. Pain scores of patients with concurrent chemotherapy and no chemotherapy during
radiation. Mean pain score for concurrent chemotherapy = 4.90 and no chemotherapy = 4.76.
Primary Cancer Type

Methods
• Management of pain throughout radiation therapy by physicians
• Patient reported pain score, pain location, frequency, descriptors, and onset are
recorded
• Pain scores on a scale from 1-10
• 0 = no pain
• 1-4 = mild pain
• 5-10 = moderate to severe pain

Figure 3. Pain scores of patients diagnosed with OC/OPC. Mean pain score for OC = 4.79 and OPC
= 4.89.

• Analysis restricted to 267 patients treated at MD Anderson for pathologically
confirmed non-metastatic OC/OPC during 2016-2021

Gender

• Patients received 6-7 weeks of radiation therapy (6000-7000 cGy) for curative intent
with end of treatment considered to be week 6 and 7
• Collected patient profiles, treatment information, and weekly pain scores
• t test performed to determine significance
• Tested at α = 0.05

Results
Variable
Chemotherapy
Concurrent
No CC
Cancer Type
OC
OPC
Gender
Male
Female
HPV Status
Positive
Negative
NA
Age
30-50 years
51-70 years
71+ years

Number

Percentage

P value

147
120

55%
45%

0.80

137
130

51%
49%

0.92

Conclusion

83
184

31%
69%

0.42

102
21
144

38%
7.9%
54.1%

Neither concurrent chemotherapy, cancer type, nor gender play a statistically significant role in
predicting patients’ pain severity during radiation therapy. Future directions include determining
additional pain prevention measures to further decrease the mild and moderate pain experienced
during treatment and increasing the cohort size. Also, exploring other clinical features such as
tumor characteristics and patients’ social history could help uncover other predictors of high pain
severity.

31
162
74

11.6%
60.7%
27.7%

Table 1. Demographics of the patient cohort. p values from t tests indicate no significant
difference across the chemotherapy, primary cancer type, and gender variables.

Figure 4. Pain scores of female and male patients diagnosed with OC/OPC. Mean pain score for
females = 4.64 and males = 4.93.
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